- Advanced search
- Immuno Portal
- Malaria Portal
Abbreviated name: FTC
Synonyms: 524W91 | BW-524W91 | Coviracil® | Emtriva®
emtricitabine is an approved drug (EMA & FDA (2003))
Compound class: Synthetic organic
Comment: Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral compound.
View more information in the IUPHAR Pharmacology Education Project: emtricitabine
|No information available.|
|Summary of Clinical Use|
|Emtricitabine is used in the treatment of HIV-1 infection in combination with other antiretroviral agents.
SARS-CoV-2 and COVID-19: A number of Phase 2/3 clinical trials are planned to evaluate the use of emtricitabine/tenofovir to prevent SARS-COV-2 transmission to healthcare professionals.
|Mechanism Of Action and Pharmacodynamic Effects|
|Emtricitabine is an analogue of cytidine and is a reverse transciptase inhibitor, preventing viral replication.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT04334928||Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel||Phase 3 Interventional||Plan Nacional sobre el Sida (PNS)|
|NCT04519125||Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia||Phase 2/Phase 3 Interventional||Hospital Universitario San Ignacio|
|NCT04405271||TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)||Phase 3 Interventional||Hospital Italiano de Buenos Aires|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)